Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets
Abstract
:1. PPARγ: Gene Structure, mRNAs, Proteins, and Related Functions
2. PPARγ Activation by Natural and Synthetic Ligands
3. PPARγ Full Agonists, Partial Agonists, and Antagonists: Distinctive Modes of Binding
4. Natural PPARγ Ligands: Cladosporols as the Model of a PPARγ Ligand
5. Different Tissues, Different Biological Processes, but a Unique Target: PPARγ
6. Conclusions and Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tontonoz, P.; Spiegelman, B.M. Fat and beyond: The diverse biology of PPARγ. Annu. Rev. Biochem. 2008, 77, 289–312. [Google Scholar] [CrossRef] [PubMed]
- Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O’Rahilly, S.; et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58, 726–741. [Google Scholar] [CrossRef] [PubMed]
- Tyagi, S.; Gupta, P.; Saini, A.S.; Kaushal, C.; Sharma, S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J. Adv. Pharm. Technol. Res. 2011, 2, 236–240. [Google Scholar] [CrossRef] [PubMed]
- Mandard, S.; Müller, M.; Kersten, S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol. Life Sci. 2004, 61, 393–416. [Google Scholar] [CrossRef] [PubMed]
- Barish, G.D.; Narkar, V.A.; Evans, R.M. PPAR delta: A dagger in the heart of the metabolic syndrome. J. Clin. Investig. 2006, 116, 590–597. [Google Scholar] [CrossRef]
- Janani, C.; Ranjitha Kumari, B.D. PPAR gamma gene—A review. Diabetes Metab. Syndr. 2015, 9, 46–50. [Google Scholar] [CrossRef]
- Medina-Gomez, G.; Gray, S.L.; Yetukuri, L.; Shimomura, K.; Virtue, S.; Campbell, M.; Curtis, R.K.; Jimenez-Linan, M.; Blount, M.; Yeo, G.S.; et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007, 3, e64. [Google Scholar] [CrossRef]
- Saraf, N.; Sharma, P.K.; Mondal, S.C.; Garg, V.K.; Singh, A.K. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. J. Pharm. Pharmacol. 2012, 64, 161–171. [Google Scholar] [CrossRef]
- Tontonoz, P.; Hu, E.; Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipidactivated transcription factor. Cell 1994, 79, 1147–1156. [Google Scholar] [CrossRef]
- Barak, Y.; Nelson, M.C.; Ong, E.S.; Jones, Y.Z.; Ruiz-Lozano, P.; Chien, K.R.; Koder, A.; Evans, R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4, 585–595. [Google Scholar] [CrossRef]
- Tang, W.; Zeve, D.; Suh, J.M.; Bosnakovski, D.; Kyba, M.; Hammer, R.E.; Tallquist, M.D.; Graff, J.M. White fat progenitor cells reside in the adipose vasculature. Science 2008, 322, 583–586. [Google Scholar] [CrossRef]
- Imai, T.; Takakuwa, R.; Marchand, S.; Dentz, E.; Bornert, J.M.; Messaddeq, N.; Wendling, O.; Mark, M.; Desvergne, B.; Wahli, W.; et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl. Acad. Sci. USA 2004, 101, 4543–4547. [Google Scholar] [CrossRef]
- Bauman, C.A.; Chokshi, N.; Saltiel, A.R.; Ribon, V. Cloning and characterization of a functional peroxisome proliferator-activated receptor gamma-responsive element in the promoter of CAP gene. J. Biol. Chem. 2000, 275, 9131–9135. [Google Scholar] [CrossRef] [PubMed]
- Nugent, C.; Prins, J.B.; Whitehead, J.P.; Wentworth, J.M.; Chatterjee, V.K.; O’Rahilly, S. Arachidonic Acid Stimulates Glucose Uptake in 3T3-L1 Adipocytes by Increasing GLUT1 and GLUT4 Levels at the Plasma Membrane Evidence for involvement of lipoxygenase metabolites and peroxisome proliferator-activated receptor. J. Biol. Chem. 2000, 276, 9149–9157. [Google Scholar] [CrossRef]
- Hollenberg, A.N.; Susulic, V.S.; Madura, J.P.; Zhang, B.; Moller, D.E.; Tontonoz, P.; Sarraf, P.; Spiegelman, B.M.; Lowell, B.B. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J. Biol. Chem. 1997, 272, 5283–5290. [Google Scholar] [CrossRef] [PubMed]
- Iwaki, M.; Matsuda, M.; Maeda, N.; Funahashi, T.; Matsuzawa, Y.; Makishima, M.; Shimomura, I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52, 1655–1663. [Google Scholar] [CrossRef] [PubMed]
- Hofmann, C.; Lorenz, K.; Braithwaite, S.S.; Colca, J.R.; Palazuk, B.B.; Hotamisligil, G.S.; Spiegelman, B.M. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994, 134, 264–270. [Google Scholar] [CrossRef] [PubMed]
- Tomaru, T.; Steger, D.J.; Lefterova, M.I.; Schupp, M.; Lazar, M.A. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor γ and and CCAAT/enhancer-binding proteins. J. Biol. Chem. 2009, 284, 6116–6125. [Google Scholar] [CrossRef]
- Jonker, J.W.; Suh, J.M.; Atkins, A.R.; Ahmadian, M.; Li, P.; Whyte, J.; He, M.; Juguilon, H.; Yin, Y.; Phillips, C.T.; et al. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012, 485, 391–394. [Google Scholar] [CrossRef]
- Dutchak, P.A.; Katafuchi, T.; Bookout, A.L.; Choi, J.H.; Yu, R.T.; Mangelsdorf, D.J.; Kliever, S.A. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148, 556–567. [Google Scholar] [CrossRef]
- Szatmari, I.; Töröcsik, D.; Agostini, M.; Nagy, T.; Gurnell, M.; Barta, E.; Chatterjee, K.; Nagy, L. PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007, 110, 3271–3280. [Google Scholar] [CrossRef] [PubMed]
- Chawla, A.; Barak, Y.; Nagy, L.; Liao, D.; Tontonoz, P.; Evans, R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7, 48–52. [Google Scholar] [CrossRef] [PubMed]
- Bouhley, M.A.; Derudas, B.; Rigamonti, E.; Dievart, R.; Brozek, J.; Haulon, S.; Zawadzki, C.; Jude, B.; Torpier, G.; Marx, N.; et al. PPArgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6, 137–143. [Google Scholar] [CrossRef] [PubMed]
- Yokoyama, Y.; Xin, B.; Shigeto, T.; Mizunuma, H. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J. Cancer Res. Clin. Oncol. 2011, 137, 1219–1228. [Google Scholar] [CrossRef] [PubMed]
- Dong, Y.W.; Wang, X.P.; Wu, K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J. Gastroenterol. 2009, 15, 441–448. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Yang, W.; Zhao, D.; Han, Y.; Liu, B.; Zhao, H.; Wang, H.; Zhang, Q.; Xu, G. Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density. Oncol. Lett. 2011, 7, 95–100. [Google Scholar] [CrossRef] [PubMed]
- Dhiman, V.K.; Bolt, M.J.; White, K.P. Nuclear receptors in cancer—Uncovering new and evolving roles through genomic analysis. Nat. Rev.Genet. 2018, 19, 160–174. [Google Scholar] [CrossRef]
- Wagner, N.; Wagner, K. Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer. Cells 2022, 11, 2432. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.G.; Lee, J.F.; Wang, S.H.; Chan, U.P.; Ip, P.C.; Lau, W.Y. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci. 2002, 70, 2631–2646. [Google Scholar] [CrossRef]
- Panigrahy, D.; Singer, S.; Shen, L.Q.; Butterfield, C.E.; Freedman, D.A.; Chen, E.J.; Moses, M.A.; Kilroy, S.; Duensing, S.; Fletcher, C.; et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Investig. 2002, 110, 923–932. [Google Scholar] [CrossRef]
- Pascual, G.; Fong, A.L.; Ogawa, S.; Gamliel, A.; Li, A.C.; Perissi, V.; Rose, D.W.; Wilson, T.M.; Rosenfeld, M.G.; Glass, C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437, 759–763. [Google Scholar] [CrossRef] [PubMed]
- Shimada, T.; Kojima, K.; Yoshiura, K.; Hiraishi, H.; Terano, A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002, 50, 658–664. [Google Scholar] [CrossRef] [PubMed]
- Thompson, E.A. PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol. Cells 2007, 24, 167–176. [Google Scholar] [CrossRef] [PubMed]
- Sarraf, P.; Mueller, E.; Jones, D.; King, F.J.; DeAngelo, D.J.; Partridge, J.B.; Holden, S.A.; Chen, L.B.; Singer, S.; Fletcher, C.; et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 1998, 4, 1046–1052. [Google Scholar] [CrossRef] [PubMed]
- Voutsadakis, I.A. Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J. Cancer Res. Clin. Oncol. 2007, 133, 917–928. [Google Scholar] [CrossRef] [PubMed]
- Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645–650. [Google Scholar] [CrossRef] [PubMed]
- Gross, B.; Pawlak, M.; Lefebvre, P.; Staels, B. PPARs in obesity-induced t2dm, dyslipidaemia and nafld. Nat. Rev. Endocrinol. 2017, 13, 36–49. [Google Scholar] [CrossRef]
- Forman, B.M.; Tontonoz, P.; Chen, J.; Brun, R.P.; Spiegelman, B.M.; Evans, R.M. 15-Deoxy-δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995, 83, 803–812. [Google Scholar] [CrossRef]
- Forman, B.M.; Chen, J.; Evans, R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA 1997, 94, 4312–4317. [Google Scholar] [CrossRef]
- Giglio, R.V.; Papanas, N.; Rozvi, A.A.; Ciaccio, M.; Patti, A.M.; Ilias, I.; Stoian, A.P.; Sahebkar, A.; Janez, A.; Rizzo, M. An update on the current and emerging use of thiazolidinediones for Type 2 Diabetes. Medicina 2022, 58, 1475. [Google Scholar] [CrossRef]
- Soccio, R.E.; Chen, E.R.; Lazar, M.A. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014, 20, 573–591. [Google Scholar] [CrossRef] [PubMed]
- Lehmann, J.M.; Moore, L.B.; Smith-Oliver, T.A.; Wilkison, W.O.; Wilson, T.M.; Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270, 12953–12956. [Google Scholar] [CrossRef] [PubMed]
- Kung, J.; Henry, R.R. Thiazolidinedione safety. Expert Opin. Drug Saf. 2012, 11, 565–579. [Google Scholar] [CrossRef] [PubMed]
- Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457–2471. [Google Scholar] [CrossRef]
- Graham, D.J.; Ouellet-Hellstrom, R.; MaCurdy, T.E.; Ali, F.; Sholley, C.; Worral, C.; Kelman, J.A. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. J. Am. Med. Assoc. 2010, 304, 411–418. [Google Scholar] [CrossRef]
- Neumann, A.; Weil, A.; Ricordeau, P.; Fagot, J.P.; Alla, F.; Allemand, H. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia 2012, 55, 1953–1962. [Google Scholar] [CrossRef]
- Wilcox, R.; Kupfer, S.; Erdmann, E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am. Heart J. 2008, 155, 712–717. [Google Scholar] [CrossRef]
- European Medicines Agency. European Medicines Agency Recommends Suspension of Avandia, Avandamet and Avaglim. 2010. Available online: https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-avandia-avandamet-avaglim (accessed on 25 July 2024).
- Mouchiroud, L.; Eichner, L.J.; Shaw, R.J.; Auwerx, J. Transcriptional coregulators: Fine-tuning metabolism. Cell Metab. 2014, 20, 26–40. [Google Scholar] [CrossRef]
- Helsen, C.; Claessens, F. Looking at nuclear receptors from anewangle. Mol. Cell. Endocrinol. 2014, 382, 97–106. [Google Scholar] [CrossRef]
- Nolte, R.T.; Wisely, G.B. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptorγ. Nature 1998, 395, 137–143. [Google Scholar] [CrossRef]
- Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med. 2004, 351, 1106–1118. [Google Scholar] [CrossRef] [PubMed]
- Pearson, S.L.; Cawthorne, M.A.; Claphametal, J.C. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-γ and aP2 in adipose tissue of high-fat-fed rats. Biochem. Biophys. Res. Commun. 1996, 229, 752–757. [Google Scholar] [CrossRef] [PubMed]
- Day, C. Thiazolidinediones: A new class of antidiabetic drugs. Diabet. Med. 1999, 16, 179–192. [Google Scholar] [CrossRef] [PubMed]
- Farce, A.; Renault, N.; Chavatte, P. Structural insight into PPARgamma ligands binding. Curr. Med. Chem. 2009, 16, 1768–1789. [Google Scholar] [CrossRef]
- Nesto, R.W.; Bell, D.; Bonow, R.O.; Fonseca, V.; Grundy, S.M.; Horton, E.S.; Le Winter, M.; Porte, D.; Semenkovich, C.F.; Smith, S.; et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108, 2941–2948. [Google Scholar] [CrossRef] [PubMed]
- Betteridge, D.J. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet. Med. 2011, 28, 759–771. [Google Scholar] [CrossRef] [PubMed]
- Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 2007, 298, 1180–1188. [Google Scholar] [CrossRef]
- Mahaffey, K.W.; Hafley, G.; Dickerson, S.; Burns, S.; Tourt-Uhlig, S.; Whyte, J.; Newby, L.K.; Komajda, M.; McMurray, J.; Bigelow, R.; et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am. Heart J. 2013, 166, 240–249. [Google Scholar] [CrossRef]
- Ryder, R.E.J. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet. Med. 2015, 32, 305–313. [Google Scholar] [CrossRef]
- Friedland, S.N.; Leong, A.; Filion, K.B.; Genest, J.; Lega, I.C.; Mottillo, S.; Poirier, P.; Reoch, J.; Eisenberg, M.J. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am. J. Med. 2012, 125, 126–133. [Google Scholar] [CrossRef] [PubMed]
- Ikeda, T. Drug-induced idiosyncratic hepatotoxicity: Prevention strategy developed after the troglitazone case. Drug Metab. Pharmacokinet. 2011, 26, 60–70. [Google Scholar] [CrossRef] [PubMed]
- Scheen, A.J. Thiazolidinediones and liver toxicity. Diabetes Metab. 2001, 27, 305–313. [Google Scholar] [PubMed]
- Matthews, L.; Berry, A.; Tersigni, M.; D’Acquisto, F.; Ianaro, A.; Ray, D. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology 2009, 150, 75–86. [Google Scholar] [CrossRef] [PubMed]
- Mieczkowska, A.; Basle, M.F.; Chappard, D.; Mabilleau, G. Thiazolidinedione induced osteocyte apoptosis by a GPR40-dependent mechanism. J. Biol. Chem. 2012, 287, 23517–23526. [Google Scholar] [CrossRef]
- Morrison, A.; Yan, X.; Tong, C.; Li, J. Acute rosiglitazone treatment is cardioprotective against ischemia- reperfusion injury by modulating AMPK, Akt and JNK signalling in nondiabetic mice. Am. J. Physiol. 2011, 301, H895–H902. [Google Scholar]
- Krocker, A.J.; Bruning, J.B. Review of structural and dynamic mechanisms of PPARγ partial agonism. PPAR Res. 2015, 2015, 816856. [Google Scholar] [CrossRef]
- Wright, M.B.; Bortolini, M.; Tadayyon, M.; Bopst, M. Minireview: Challenges and Opportunities in Development of PPAR Agonists. Mol. Endocrinol. 2014, 28, 1756–1768. [Google Scholar] [CrossRef]
- Oberfield, J.L.; Collins, J.L.; Holmes, C.P.; Goreham, D.M.; Cooper, J.P.; Cobb, J.E.; Lenhard, J.M.; Hull-Ryde, E.A.; Mohr, C.P.; Blanchard, S.G.; et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. USA 1999, 96, 6102–6106. [Google Scholar] [CrossRef]
- Bruning, J.B.; Chalmers, M.J.; Prasad, S.; Busby, S.A.; Kamenecka, T.M.; He, Y.; Nettles, K.W.; Griffin, P.R. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 2007, 15, 1258–1271. [Google Scholar] [CrossRef]
- Amano, Y.; Yamaguchi, T.; Ohno, K.; Niimi, T.; Orita, M.; Sakashita, H.; Takeushi, M. Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens. Res. 2012, 35, 715–719. [Google Scholar] [CrossRef]
- Pochetti, G.; Godio, C.; Mitro, N.; Caruso, D.; Galmozzi, A.; Scurati, S.; Loiodice, F.; Fracchiolla, G.; Tortorella, P.; Laghezza, A.; et al. Insights into the mechanism of partial agonism: Crystal structures of the peroxisome proliferatoractivated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands. J. Biol. Chem. 2007, 282, 17314–17324. [Google Scholar] [CrossRef] [PubMed]
- Waku, T.; Shiraki, T.; Oyama, T.; Fujimoto, Y.; Maebara, K.; Kamiya, N.; Jingami, H.; Morikawa, K. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. J. Mol. Biol. 2008, 385, 188–199. [Google Scholar] [CrossRef]
- Itoh, T.; Fairall, L.; Amin, K.; Inaba, Y.; Szanto, A.; Balint, B.L.; Nagy, L.; Yamamoto, K.; Schwabe, J.W. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 2008, 15, 924–931. [Google Scholar] [CrossRef] [PubMed]
- Malapaka, R.R.; Khoo, S.; Zhang, J.; Choi, J.H.; Zhou, X.E.; Xu, Y.; Gong, Y.; Li, J.; Yong, E.L.; Chalmers, M.J.; et al. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J. Biol Chem. 2012, 287, 183–195. [Google Scholar] [CrossRef]
- Leesnitzer, L.M.; Parks, D.J.; Bledsoe, R.K.; Cobb, J.E.; Collins, J.L.; Consler, T.G.; Davis, R.G.; Hull-Ride, E.A.; Lenhard, J.M.; Patel, L.; et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002, 41, 6640–6650. [Google Scholar] [CrossRef]
- Nagy, L.; Tontonoz, P.; Alvarez, J.G.A.; Chen, H.; Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998, 93, 229–240. [Google Scholar] [CrossRef]
- Xu, H.E.; Lambert, M.H.; Montana, V.G.; Parks, D.J.; Blanchard, S.G.; Brown, P.J.; Sternbach, D.D.; Lehmann, J.M.; Wisely, G.B.; Willson, T.M.; et al. Molecular recognition of fatty acids by peroxisome proliferator activated receptors. Mol. Cell 1999, 3, 397403. [Google Scholar] [CrossRef] [PubMed]
- Ziouzenkova, O.; Perrey, S.; Asatryan, L.; Hwang, J.; MacNaul, K.L.; Moller, D.E.; Rader, D.J.; Sevanian, A.; Zechner, R.; Hoefler, G.; et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase. Proc. Natl. Acad. Sci. USA 2003, 100, 2730–2735. [Google Scholar] [CrossRef] [PubMed]
- Hughes, T.S.; Giri, P.K.; de Vera, I.M.S.; Marciano, D.P.; Kuruvilla, D.S.; Shin, Y.; Blayo, A.L.; Kamenecka, T.M.; Burris, T.P.; Griffin, P.R.; et al. An alternate binding site for PPARγ ligands. Nat. Commun. 2014, 5, 3571. [Google Scholar] [CrossRef] [PubMed]
- Shang, J.; Brust, R.; Mosure, S.A.; Bass, J.; Tello, P.M.; Lin, H.; Hughes, T.S. Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ. eLife 2018, 7, e43320. [Google Scholar] [CrossRef]
- Hurtado, O.; Ballesteros, I.; Cuartero, M.I.; Moraga, A.; Pradillo, J.M.; Ramirez-Franco, J.; Bartolomè-Martin, D.; Pascual, D.; Torres, M.; Sanchez-Prieto, J.; et al. Daidzein has neuroprotective effects through ligand-binding independent PPARgamma activation. Neurochem. Int. 2012, 61, 119–127. [Google Scholar] [CrossRef]
- Robbins, G.T.; Nie, D. PPAR gamma, bioactive lipids, and cancer progression. Front. Biosci. 2012, 17, 1816–1834. [Google Scholar] [CrossRef] [PubMed]
- Waku, T.; Shiraki, T.; Oyama, T.; Maebara, K.; Nakamori, R.; Morikawa, K. The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites. EMBO J. 2010, 29, 3395–3407. [Google Scholar] [CrossRef] [PubMed]
- Nasini, G.; Arnone, A.; Assante, G.; Bava, A.; Moricca, S.; Ragazzi, A. Secondary metabolites of Cladosporium tenuissimum, a hyperparasite of rust fungi. Phytochemistry 2004, 65, 2104–2111. [Google Scholar] [CrossRef]
- Moricca, S.; Ragazzi, A.; Assante, G. Biocontrol of rust fungi by Cladosporium tenuissimum. In Rust Diseases of Willow and Poplar; Hao Pei, M., McCracken, A.R., Eds.; CABI Publishing: Wallingford, UK, 2005; pp. 213–229. [Google Scholar]
- Moricca, S.; Ragazzi, A.; Mitchelson, K.R.; Assante, G. Antagonism of the Two-Needle Pine Stem Rust Fungi Cronartium flaccidum and Peridermium pini by Cladosporium tenuissimum In Vitro and In Planta. Phytopathology 2001, 91, 457–468. [Google Scholar] [CrossRef] [PubMed]
- Zurlo, D.; Leone, C.; Assante, G.; Salzano, S.; Renzone, G.; Scaloni, A.; Foresta, C.; Colantuoni, V.; Lupo, A. Cladosporol A stimulates G1-phase arrest of the cell cycle by up-regulation of p21waf1/cip1 expression in human colon carcinoma HT-29 cells. Mol. Carcinog. 2013, 52, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Zurlo, D.; Assante, G.; Moricca, S.; Colantuoni, V.; Lupo, A. Cladosporol A, a new Peroxisome Proliferator-Activated Receptor γ (PPARγ) ligand, inhibits colorectal cancer cells proliferation through β-catenin/TCF pathway inactivation. Biochim. Biophys. Acta 2014, 1840, 2361–2372. [Google Scholar] [CrossRef]
- Zurlo, D.; Ziccardi, P.; Votino, C.; Colangelo, T.; Cerchia, C.; Dal Piaz, F.; Dallavalle, S.; Moricca, S.; Novellino, E.; Lavecchia, A.; et al. The antiproliferative and proapoptotic effects of cladosporols A and B are related to their different binding mode as PPARγ ligands. Biochem. Pharmacol. 2016, 108, 22–35. [Google Scholar] [CrossRef]
- Fracchiolla, G.; Laghezza, A.; Piemontese, L.; Parente, M.; Lavecchia, A.; Pochetti, G.; Montanari, R.; Di Giovanni, C.; Carbonara, G.; Tortorella, P.; et al. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors alpha/gamma dual agonists. Bioorg. Med. Chem. 2012, 20, 2141–2151. [Google Scholar] [CrossRef]
- Porcelli, L.; Gilardi, F.; Laghezza, A.; Piemontese, L.; Mitro, N.; Azzariti, A.; Altieri, F.; Cervoni, L.; Fracchiolla, G.; Giudici, U.; et al. Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. J. Med. Chem. 2012, 55, 37–54. [Google Scholar] [CrossRef] [PubMed]
- Vasaturo, M.; Fiengo, L.; De Tommasi, N.; Sabatino, L.; Ziccardi, P.; Colantuoni, V.; Bruno, M.; Cerchia, C.; Novellino, E.; Lupo, A.; et al. A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability. Sci. Rep. 2017, 7, 41273. [Google Scholar] [CrossRef] [PubMed]
- Sabatino, L.; Ziccardi, P.; Cerchia, L.; Muccillo, L.; Piemontese, F.; Loiodice, F.; Colantuoni, V.; Lupo, A.; Lavecchia, A. Chiral phenoxyacetic acid analogue inhibit colon cancer cell proliferation acting as PPARγ partial agonists. Sci. Rep. 2019, 9, 5434. [Google Scholar] [CrossRef] [PubMed]
- Rapuano, R.; Ziccardi, P.; Cioffi, V.; Dallavalle, S.; Moricca, S.; Lupo, A. Cladosporol A and B, two natural peroxisome proliferator-activated receptor gamma (PPARγ) agonists, inhibit adipogenesis in 3T3-L1 cells preadipocytes and cause a conditioned–culture-medium-dependent arrest of HT-29 cell proliferation. BBA-Gen. Subj. 2021, 1865, 129973. [Google Scholar] [CrossRef] [PubMed]
- Rapuano, R.; Riccio, A.; Mercuri, A.; Madera, J.R.; Dallavalle, S.; Moricca, S.; Lupo, A. Proliferation and migration of PC-3 prostate cancer cells is counteracted by PPARγ-cladosporol binding-mediated apoptosis and a decreased lipid biosynthesis and accumulation. Biochem. Pharmacol. 2024, 222, 116097. [Google Scholar] [CrossRef] [PubMed]
- Li, F.; Lu, T.; Liu, D.; Zhang, C.; Zhang, Y.; Dong, F. Upregulated PPARG2 facilitates interaction with demethylated AKAP12 gene promoter and suppresses proliferation in prostate cancer. Cell Death Dis. 2021, 12, 528. [Google Scholar] [CrossRef] [PubMed]
- Dong, F.; Liu, D.; Lu, T.; Li, F.; Zhang, C.; Qun, E.; Zhang, Y. PPARγ2 functions as a tumor suppressor in a translational mouse model of human prostate cancer. Asian J. Androl. 2022, 24, 90–96. [Google Scholar] [PubMed]
- Medes, G.; Thomas, A.; Weinhouse, S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953, 13, 27–29. [Google Scholar] [PubMed]
- Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]
- De Berardinis, R.J.; Chandel, N.S. Fundamentals of cancer metabolism. Sci. Adv. 2016, 2, e1600200. [Google Scholar]
- Mohler, J.L.; Titus, M.A.; Bai, S.; Kennerley, B.J.; Lih, F.B.; Tomer, K.B.; Wilson, E.M. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011, 15, 1486–1496. [Google Scholar] [CrossRef]
- Montgomery, R.B.; Mostaghel, E.A.; Vessella, R.; Hess, D.L.; Kalhorn, T.F.; Higano, C.S.; True, L.D.; Nelson, P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68, 4447–4454. [Google Scholar] [CrossRef] [PubMed]
- Shang, J.; Koietin, D.J. Structural mechanism underlying ligand binding and activation of PPARγ. Structure 2021, 29, 940–950. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rapuano, R.; Mercuri, A.; Dallavalle, S.; Moricca, S.; Lavecchia, A.; Lupo, A. Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets. Biomolecules 2024, 14, 998. https://doi.org/10.3390/biom14080998
Rapuano R, Mercuri A, Dallavalle S, Moricca S, Lavecchia A, Lupo A. Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets. Biomolecules. 2024; 14(8):998. https://doi.org/10.3390/biom14080998
Chicago/Turabian StyleRapuano, Roberta, Antonella Mercuri, Sabrina Dallavalle, Salvatore Moricca, Antonio Lavecchia, and Angelo Lupo. 2024. "Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets" Biomolecules 14, no. 8: 998. https://doi.org/10.3390/biom14080998